Autoimmune diseases include more than 70 different conditions affecting approximately 5% of the population of developed countries[@b1]; they are a major health problem and can greatly impair the quality of life of affected subjects. Primary biliary cholangitis (PBC), until recently known as Primary Biliary Cirrhosis[@b2][@b3][@b4][@b5][@b6][@b7][@b8][@b9], is considered a model autoimmune disease because of the homogeneity among patients and the high disease specificity of the accompanying anti-mitochondrial and antinuclear antibodies (AMA, ANA); there has been an enormous effort in studying PBC in both humans and murine models[@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23]. The pathogenesis of PBC remains enigmatic despite the well-established influence of environmental and genetic factors and including extensive immunological data[@b11][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30]. Reliable epidemiological data could suggest clues to etiology by identifying environmental factors, which initiate the disease in predisposed individuals. According to earlier data[@b24][@b31][@b32] PBC is considered a disease predominantly affecting women with female:male (F:M) ratios of up to 10:1 and is therefore a prime example of the characteristic sexual dimorphism in autoimmunity. There is a wide variation among studies of incidence and prevalence rates, with rates increasing over time[@b29][@b32][@b33]. Thus the annual incidence and prevalence rates of PBC per 100,000 inhabitants have ranged from 0.33--5.8 per 100,000 and 1.91--40.2, respectively[@b34]; attributed to ethnic differences in study populations, methods, and case ascertainment. Most epidemiological studies are performed in developed countries. True population-based studies are scarce, and studies based on case finding are subject to obvious shortcomings which pertain also for other autoimmune diseases[@b35]. Indeed, there have been multiple attempts to understand the female predominance in a variety of autoimmune and inflammatory diseases[@b36][@b37][@b38].

Administrative databases are an alternative data source that should overcome some of the weaknesses evident in previous studies[@b39][@b40] and herein we assess data derived from two such databases, for Lombardia, Italy and for Denmark, regions located at latitudinal extremes of continental Europe. Thus we aimed to compare the overall mortality, incidence and prevalence of PBC in two well-defined population-based studies over a recent decade, 2000--2009, considering also sex ratios and mortality. Lombardia, is a Northern Italian province with a population of some 9.7 million, Denmark counts nearly 5.5 million inhabitants.

Patients and Methods
====================

Data sources and study population
---------------------------------

Two databases were used to identify subjects with PBC and retrieve data, the administrative database of the inpatient population in Lombardia, a Northern Italian province with a population of 9.7 million, and Denmark with a population of about 5.5 million, using the Danish National Patient Registry.

Lombardia accommodates 191 health facilities, including 29 public academic and community hospitals, records over 150 million out-patient visits and provides over 2 million hospital admissions annually. The administrative database contains information on all patients discharged from any hospital in the region, and includes sex, date of birth, discharge diagnoses based on the WHO International Classification of Diseases 9^th^ Edition, Clinical Modification (ICD-9-CM)[@b41], dates of hospitalization and discharge, and date and cause of death for patients who died in hospital; data were recorded since 2000. Moreover, all Italian citizens enjoy universal, tax-financed healthcare, enabling access to diagnostic and therapeutic procedures in public hospitals after the charge of a co-payment; subjects affected by chronic diseases, including PBC, can obtain a disease-specific exemption code that frees them from the co-payment. Given that the exemption code frees subjects affected by a chronic disease from the co-payment due for visits and procedures, the number of affected patients that do not request the exemption code is almost nil. Therefore, the exemption code was used in this study to supplement the inpatient registry since it allows identification of PBC patients that never required hospitalization. The study population included subjects over 20 years of age with "Biliary cirrhosis" (571.6) as the primary or secondary diagnosis between January 1^st^, 2000 and December 31^st^ 2009. The date of PBC diagnosis was defined as the date on which patients received their first such diagnosis. Individual information from the register was linked to a serial number by a third party to preserve anonymity. We obtained dates of all cause of death only from in-hospital events since it was not possible to obtain them from the exemption code. Indeed, there is no updating of the exemption data due to death or emigration. Prevalence was calculated matching data from hospital access of PBC patients from 2000 to 2009 and active exemption codes, since the exemption code allowed us to identify PBC patients that were not admitted into a hospital during the study time.

In order to compare our results with those for a different population and jurisdiction, and given that outpatients are not included in the Lombardia administrative database, we accessed the Danish National Patient Registry and identified all Danish citizens diagnosed with PBC during 2000--2009. Denmark has a population of 5.5 million, and the Registry has recorded data from all admissions to Danish non-psychiatric hospitals since 1977[@b42]. We selected the same information as that included in the Lombardia study, however discharge diagnoses were based on ICD-8 in 1977--1993 and since 1994 on ICD-10. 'Primary biliary cirrhosis' was defined by the code K74.3 in ICD-10, so differing from 'secondary biliary cirrhosis' (K74.4) and 'non-specific biliary cirrhosis' (K74). The date of PBC diagnosis was defined as the date on which patients received their first PBC diagnosis, and patients diagnosed with PBC before 2000 were excluded. Dates of death were obtained from the Danish Central Office of Civil Registration System, which tracks the vital status of Danish residents and is continuously updated[@b43].

Statistical analysis
--------------------

The incidence rate was defined and computed as the number of patients with a first-time diagnosis of PBC in a particular year divided by the total number of inhabitants at the beginning of that year. For Lombardia, we used a 4 year washout period (2000--2004) to avoid including prevalent cases due to the fact that data recording started in 2000, and determined a 6 year span time (from Jan 1^st^ 2004 to Dec 31^st^ 2009) with no significant variation of the Standardized Incidence Ratio (SIR) (Poisson regression rate P = 0.15). The incidence rate for a range of years was obtained by summing the numerator and denominator for each year. All incidence rates were age-standardized to the WHO Standard Population[@b41] with the direct standardization method and 95% confidence intervals (CI) based on the Poisson distribution. The prevalence was computed as the proportion of citizens with PBC divided by the total number of citizens at the beginning of each year, again standardized to the WHO Standard Population. We used the Kaplan-Meier method to estimate survival probabilities, and we used Cox regression to estimate the mortality hazard ratio for men versus women adjusting for age at diagnosis and calendar year of diagnosis, both entered as continuous variables. Relative survival analysis was performed in order to estimate PBC patients' survival with respect to that of the general population. The analysis was performed using public open access databases reporting general population all causes mortality, including separate data for sex and class of age. All statistical analyses were done using Stata statistical software 12.0 (Stata Corporation, College Station, TX, USA).

Results
=======

Incidence, prevalence, and female:male ratio
--------------------------------------------

On Jan 1^st^ 2010 there were 9,742,676 registered residents in Lombardia. Among these, the PBC cohort comprised 2,970 patients of whom 2,073 (69.8%) were female. The mean age at diagnosis was 61.7 (95% CI 61.5--62.7), with a slight, but statistically significant, difference between males (60.8 years) and females (62.1 years). A 2.3:1 F:M ratio was observed for this PBC cohort. In Denmark, among 5,534,738 residents, there were 722 PBC cases identified, 584 females and 138 males in the 10-year observation time with the F:M ratio being 4.2:1. The mean age at diagnosis was 60.7 years, 59.3 in males and 61.1 in females.

SIRs of PBC for Lombardia, standardized on a WHO Standard Population[@b41], was 16.7 per million/year during 2004--2009, compared to 11.4 million/year in Denmark ([Table 1A](#t1){ref-type="table"}). However the trend between both populations was not homogeneous as confirmed by the regression model applied (Lombardia Poisson regression rate p \< 0.0005, Denmark Poisson regression rate p = 0.48) ([Fig. 1A](#f1){ref-type="fig"}). We hypothesize that, since no administrative data in Lombardia were available before 2000, in the first years after 2000 there would be a mix of truly incident patients and patients who were in fact diagnosed with PBC before 2000. We therefore assume a 4-year washout was needed in order to avoid SIR overestimation and determined a six-year span time (from Jan 1^st^ 2004 to Dec 31^st^ 2009) with no significant variation of SIR (p = 0.15) ([Fig. 1B](#f1){ref-type="fig"}). The sex-specific SIR shows that the F:M ratio remained constant over the studied decade in both Lombardia and Denmark (data not shown).

The mean point prevalence of PBC in Lombardia in 2009 was 160 cases per million (234 female, 81 male) [Table 1B](#t1){ref-type="table"}. The prevalence in 2009 seems to be the most reliable one for Lombardia since the rate did not reach a plateau during the follow-up period ([Fig. 2](#f2){ref-type="fig"}). Indeed, whereas point prevalence remains constant during the study time in Denmark (Poisson P = 0.12), it increases from 2000 to 2009 (P \< 0.0005) ([Fig. 2A,B](#f2){ref-type="fig"}). Such dynamics seem to be related to the method in use for diagnosis identification. In Lombardia a diagnosis of PBC was made at admission to the hospital starting from 2000 whereas Danish registries recorded a prevalent diagnosis even if it was made before 2000. In order to avoid this limitation we put together the exemption code registry in Lombardia and the inpatient registry data, eliminate duplicates, and calculated the point prevalence in 2010 which was 295 cases per million (486 female, 159 male)

Survival and prognostic factors: males fare badly/do worse
----------------------------------------------------------

2,970 incident PBC cases in Lombardia were observed for a mean follow-up of 4.8 years, and 14,446 person-year from PBC diagnosis. The 1, 5 and 10 year survival rate estimation was respectively 86% (CI 85--87%), 70% (CI 69--72%) and 61% (CI 59--64%) ([Fig. 3A](#f3){ref-type="fig"}). The sex specific survival at 1, 5 and 10 years was significantly higher for females (n = 2,073), respectively 89% (CI 88--91%), 77% (CI 75--78%) and 67% (CI 65--70%) than for males (n = 897), respectively 78% (CI 75--80%), 55% (CI 52--59%) and 47% (CI 43--51%) ([Fig. 3B](#f3){ref-type="fig"}). In Denmark a survival analysis was done by following 722 incident cases for 2,780 person-years from PBC diagnosis, with an mean follow up of 3.9 years. Survival rate estimates, at 1, 5 and 10 years, were similar to those observed in Lombardia, respectively 87% (CI 84--89%), 67% (CI 63--71%) and 54% (CI 48--60%) ([Fig. 3C](#f3){ref-type="fig"}). The sex specific survival rate in Denmark resembled the higher mortality in men with PBC observed in Lombardia since, in Denmark, survival of females at 1, 5 and 10 years was 90% (IC 87--92%), 73% (CI 69--77%) and 60% (CI 53--67%) and in males, 72% (CI 63--79%), 42% (CI 32--51%) and 27% (CI 14--43%) ([Fig. 3D](#f3){ref-type="fig"}). Most importantly the relative survival analysis demonstrated that the higher mortality in men with PBC was independent of the higher male mortality in the general population ([Fig. 4](#f4){ref-type="fig"}).

Using the Cox proportional hazard model, including sex, age at diagnosis and year of diagnosis ([Table 2](#t2){ref-type="table"}), male sex was associated with a higher risk of all-causes death for both populations: Hazard Ratio (HR) 2.36 in Lombardia, and 3.04 in Denmark.

Discussion
==========

In the present study we report the epidemiology and natural history of PBC for two populations, Lombardia and Denmark, reflecting two diverse latitudes of continental Europe. Our findings include a significantly lower than hitherto cited F:M ratio for both the Italian and Danish populations, a probable decrease in incidence over time (particularly for Lombardia), a lack of any latitudinal prevalence gradient, and a surprisingly higher overall mortality for male than female PBC patients for both populations.

One strength of our study is the use of population-based databases, which obviates the selection bias inherent in studies restricted to just a single or a few health facilities or reference centers. The use of administrative data has been well validated for the Danish model, ensuring registration of any event within the health system of defined geographical boundaries[@b40].

Previous epidemiological research on PBC, mainly European, has reported incidence rates ranging from 2 to 49 cases per million/year and prevalence of between 19 and 402 cases per million ([Table 3](#t3){ref-type="table"})[@b32]; our data fit within the wide range reported and are significantly different among them. Of note, our data showed that the trend between both populations was not homogeneous with an apparent decrease in incidence over time especially in Lombardia. We hypothesize that, since no administrative data in Lombardia were available before 2000, in the first years after 2000 there would be a mix of truly incident patients and patients who were in fact diagnosed with PBC before 2000. Indeed, assuming a 4-year washout was needed in order to avoid SIR overestimation, no significant variation of SIR was determined.

On the other side, the much larger number of diagnoses of PBC in Lombardia may be explicable by a heightened awareness of physicians to liver diseases since, in Italy as in other Mediterranean countries, there is a higher prevalence of viral hepatitis. Moreover, the heterogeneity of epidemiological data can be the result of demographic changes, increasing survival, earlier diagnosis, improved treatment and greater recognition of the disease by physicians and patients[@b32]. Furthermore, the diagnostic rate of PBC may have overall increased during these years.

The ratio of females to males with PBC in Lombardia was 2.3:1, lower than that observed in Denmark (4.2:1); however, in both cohorts the female:male ratio was far lower than any other sex ratio previously reported ([Table 3](#t3){ref-type="table"}). Of note, two other large epidemiological studies based on administrative data demonstrate a higher than expected presence of male PBC patients ([Table 4](#t4){ref-type="table"})[@b44][@b45]. One of these is a recent paper comprising data from 33 different autoimmune disease patients from administrative databases in Sweden[@b44]. The authors included 2,852 PBC patients, 1,080 of which were male, showing a female: male ratio of 1.6:1, in accordance with the trend revealed by our data and other population based studies[@b45]. Data obtained from reference centers demonstrate that prevalence is strongly biased to females (9:1), possibly influenced by the greater use by women of medical check-ups in highly specialized centers. The present analysis of population-wide registers, however, reflects a muted difference in the frequency of PBC between the sexes more in conformity with that seen in other autoimmune diseases.

Importantly, besides the differences in incidence and prevalence in Northern Italy and Denmark, the relatively higher mortality in male PBC patients was consistent in both datasets. Indeed, male sex was confirmed to be an independent predictor of all-cause mortality in both populations. This finding has been reported once[@b46], but has not been generally replicated[@b47][@b48]; however, the Canadian epidemiological study[@b45] did report male sex as an independent predictor of mortality (HR 5.06). Several hypotheses can be offered for the causes of increased male mortality, including lack of compliance, additional environmental exposures and unknown sex factors that may modulate immunity. Thus, Carbone *et al*. in a recent study from UK, showed that men were significantly less likely to have responded to ursodeoxycholic acid (UDCA) than women; male sex was an independent predictor of nonresponse on multivariate analysis[@b49]. Moreover, Carbone and colleagues reported than men were less likely to be symptomatic, which may be a cause of delay in diagnosis[@b49]. Unfortunately no data regarding symptoms, use of UDCA and adherence to therapy were available in our database; similarly no clinical data were available in our database that would have helped to ascertain whether liver-related deaths were more frequent. We used the need for liver transplant as a surrogate endpoint for liver related death, but only 39 PBC patients in Demark and 58 in Lombardia were transplanted during the decade of study, suggesting that there was no association.

Our study has some weaknesses that could, at least in part, explain the reported differences between the two included populations. First, the diagnosis code used in Lombardia (ICD-9-CM 571.6) identifies cases of biliary cirrhosis including therefore cases of secondary biliary cirrhosis. Unfortunately, with ICD-9 secondary biliary disease that cannot be excluded, which reduces the specificity and may explain the higher number of cases of PBC reported in Lombardia. Of note, primary sclerosing cholangitis (PSC) has its own code in the Italian system and, therefore, no PSC patients were included. Second, a non-coded diagnosis of PBC at release from the hospital, as well as among outpatients with no exemption code would not be identified in the Italian database whereas the Denmark Registry does include that information. Third we obtained dates of death only from in-hospital events since it was not possible to obtain these from the exemption code. This will probably lead to underestimation of overall mortality, however it will not change the male: female ratio.

In conclusion, our population studies based on disease registers questions some long-held beliefs on determinants of PBC. Females, although more frequently affected by PBC, seem to have a better outcome. Our findings clearly define an important clinical message for the hepatologist: male PBC patients have higher mortality than their female counterparts, such that close clinical follow-up and checking adherence to therapy are strongly recommended. In addition, a steadily increasing prevalence in Lombardia points to possible unsuspected environmental effects in causation, at least in that population, although biased estimation due to factors like increasing awareness of the disease or increasing hospitalization of patients cannot be excluded. Finally, the cause(s) of increased male mortality in PBC calls for a larger and prospective study and should be addressed in the future with well-designed observational trials.
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![Standard incidence rate in Lombardia and Denmark.\
(**A**) the trend between both populations was not homogeneous as confirmed by the regression model applied (Lombardia Poisson regression rate P \< 0.0005, Denmark Poisson regression rate P = 0.48). (**B**) We therefore assume a 4-year washout in order to avoid SIR overestimation and determined a six year span time (from Jan 1^st^ 2004 to Dec 31^st^ 2009) with no significant variation of SIR (P = 0.15).](srep25906-f1){#f1}

![PBC point prevalence in Lombardia and Denmark from 2000 to 2009.\
The figure shows that whereas point prevalence remains constant during the study time in Denmark (Poisson P = 0.12), it increases from 2000 to 2009 (P \< 0.0005) **(A,B)**. This dynamics is observed in both male and females **(A**).](srep25906-f2){#f2}

![Survival and sex specific survival from diagnosis in Lombardia (**A,B**) and Denmark (**C,D**). The figure shows higher mortality of PBC male patients in both populations. CI of 95%.](srep25906-f3){#f3}

![Relative survival rates (RSR) for PBC, by sex in both Lombardian and Danish population.\
The figure shows lower RSR of PBC male patients in both populations, all the groups show RSR \< 1. Bands indicate 95% CI.](srep25906-f4){#f4}

###### (A) Standardized incidence rate in Lombardia and Denmark.

  A                                                                      
  ------------ ------ ------ ------------------- ---------- ------ ----- -------------------
  2000          55.4   21.9   39.1 (35.5--42.7)     2000     17.6   3.5   10.7 (8.0--13.4)
  2001          41.0   20.4   31.1 (27.9--34.3)     2001     18.2   5.5   12.1 (9.3--14.9)
  2002          34.1   17.2   26.4 (23.4--29.3)     2002     19.5   4.6   12.3 (9.5--15.1)
  2003          30.5   16.3   23.9 (21.0--26.7)     2003     21.9   4.4   13.4 (10.5--10.5)
  2004          25.7   13.1   19.5 (17.0--22.0)     2004     20.0   6.2   13.1 (10.3--16.0)
  2005          21.7   12.8   17.5 (15.2--20.2)     2005     18.2   5.9   12.2 (9.5--14.9)
  2006          27.9   11.4   20.4 (17.7--23.1)     2006     16.3   5.1   10.9 (8.3--13.6)
  2007          21.1   9.8    16.2 (13.8--18.6)     2007     14.2   3.3    8.4 (6.5--11.2)
  2008          18.7   9.1    14.1 (12.0--16.2)     2008     18.7   4.3   11.7 (9.1--14.4)
  2009          16.1   8.3    12.6 (10.5--14.7)     2009     13.3   4.9    9.1 (6.8--11.4)
  2004--09      21.9   10.7   16.7 (14.4--19.1)   2000--09   17.7   4.7   11.4 (10.6--12.3)
  **B**                                                                  
  2000           52     19       36 (33--40)                 174    33      107 (99--115)
  2001           90     32       62 (57--66)                 178    31     108 (100--116)
  2002          119     44       82 (77--88)                 178    33     109 (101--117)
  2003          143     56      100 (94--106)                184    35     113 (104--121)
  2004          162     61     113 (106--119)                191    34     116 (108--125)
  2005          177     66     123 (117--129)                197    35     120 (111--128)
  2006          199     70     136 (129--143)                197    37     120 (112--129)
  2007          213     74     146 (139--153)                200    35     121 (112--129)
  2008          226     77     154 (146--161)                198    36     120 (112--129)
  2009          234     81     160 (152--167)                203    35     122 (114--131)
  2000--2009    162     58     111 (109--113)                190    34     115 (113--118)

For Lombardia, we used a 4 year washout period (2000--2004) to avoid including prevalent cases and determined a 6 year span time (from Jan 1^st^ 2004 to Dec 31^st^ 2009) with no significant variation of the Standardized Incidence Ratio (SIR). (**B**) Point prevalence of PBC in Lombardia and Denmark from 2000 to 2009.

###### Cox regression model for predictors of mortality in PBC (2000--2009).

  Factor                   LOMBARDIA            DENMARK
  ------------------- ------------------- -------------------
  Male sex             2.36 (2.08--2.69)   3.04 (2.31--4.01)
  Age at diagnosis     1.06 (1.06--1.07)   1.07 (1.06--1.08)
  Year of diagnosis    1.29 (1.24--1.34)   1.19 (1.11--1.29)

###### Epidemiological studies on PBC.

  Area                         Year   Patients (n)   Prevalence (per 10^6^)   Incidence (10^6^/year)   Age (years)   Sex rate (F:M)
  --------------------------- ------ -------------- ------------------------ ------------------------ ------------- ----------------
  Europe[@b50]                 1984       569                  23                       54                 54             10:1
  Sweden[@b51]                 1985       111                 151                      13,3                55             6:1
  Newcastle, UK[@b52]          1989       347                 154                       19                 58             9:1
  Ontario, Canada[@b53]        1990       225                  22                      3,3                 59             13:1
  Estonia[@b54]                1995        69                  27                      2,3                 --              22
  Newcastle, UK[@b55]          1997       160                 240                       22                 66             10:1
  Norway[@b56]                 1998        21                 146                       16                 --             9:1
  Minnesota, USA[@b57]         2000        46                 402                       27                 --             8:1
  Newcastle, UK[@b58]          2001       770                 251                       31                 --             10:1
  Victoria, Australia[@b59]    2004       249                  51                       --                 61             9:1
  Japan[@b60]                  2005       9761                 78                       --                 --             9:1
  Canada[@b45]                 2009       137                 227                       30                 53             5:1
  Denmark                      2011       722                 115                      11.2                61            4.2:1
  Lombardia                    2011       2970                160                      16.7                62            2.3:1

###### Population based epidemiological studies demonstrating high female:male ratio in PBC.

  Area                Years (range)   Subjects included   Sex rate (F:M)    Ref.
  ------------------ --------------- ------------------- ---------------- --------
  Canada               1996--2002         1,100,000           4.8:1        [@b45]
  Sweden               1964--2008          535,538            1.6:1        [@b44]
  Denmark              2000--2009         5,500,000           4.2:1          --
  Lombardy (Italy)     2000--2009         9,700,000           2.3:1          --

Two large epidemiological data sets are compared to the data obtained from administrative data in Lombardy (Italy) and Denmark and reported in the present study.
